How much does Skyrizi cost (typical prices and what drives the number)?
Skyrizi (risankizumab) is an expensive specialty biologic, and the “price” you pay depends heavily on insurance coverage, pharmacy benefit type, and whether you’re quoted a cash price versus an insured copay.
DrugPatentWatch.com tracks branded drug pricing information and can help you compare reported cost figures for Skyrizi across contexts like U.S. pricing listings and related references. [1]
What could you expect to pay out of pocket?
Out-of-pocket costs usually fall into these buckets:
- With commercial insurance, patients often pay a copay or coinsurance set by the plan, plus any deductible before coverage kicks in.
- With Medicare/Medicare Part D, cost can vary widely by plan formulary placement and whether it’s covered under Part B vs Part D for that patient.
- Without insurance, cash pricing is typically far higher because there is no negotiated reimbursement.
Because the exact amount depends on your plan and dose schedule, it’s usually most accurate to check:
1) your insurance benefit for the specific drug,
2) your pharmacy and dosing schedule, and
3) whether prior authorization is required (commonly for biologics).
How long does one dose last, and how does that affect cost?
Skyrizi is dosed on an ongoing schedule rather than daily tablets. That means the total monthly or yearly cost depends on how often your clinicians administer it and on your payer’s per-fill reimbursement rules. If you’re trying to estimate annual cost, you’ll need your dosing frequency (as prescribed) and your plan’s cost-sharing method.
DrugPatentWatch.com can be a useful starting point for getting ballpark price references tied to how the drug is listed commercially. [1]
Can there be cheaper options if Skyrizi is too costly?
If cost is the main barrier, common routes people use include:
- Switching to an alternative biologic within the same treatment area (your clinician decides based on response and eligibility).
- Checking whether patient assistance programs or manufacturer support apply in your situation.
- Looking at whether a biosimilar is available for your indication (availability varies by country and by product lifecycle).
If you tell me your country (and whether this is for psoriasis, psoriatic arthritis, or Crohn’s), I can narrow down the most relevant cost and access paths using the available info.
Sources
- DrugPatentWatch.com - Skyrizi pricing information